# Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients

> **NCT02474420** · NA · UNKNOWN · sponsor: **Kevin H.M. Kuo, MD, MSc, FRCPC** · enrollment: 60 (estimated)

## Conditions studied

- Beta-Thalassemia
- Iron Overload

## Interventions

- **DRUG:** Amlodipine
- **DRUG:** Deferasirox

## Key facts

- **NCT ID:** NCT02474420
- **Lead sponsor:** Kevin H.M. Kuo, MD, MSc, FRCPC
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-06
- **Primary completion:** 2017-06
- **Final completion:** 2018-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02474420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02474420, "Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02474420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*